Full Papers
Uncovering risk factors for adverse events and infections in rheumatoid arthritis and rheumatoid arthritis with interstitial lung disease under treatment with biologics or targeted synthetic DMARDs: insights from the KOBIO Registry
J.-W. Kim1, K. Shin2, J. Jung3, C.-H. Suh4, J. Kim5, S.-K. Lee6, H.-A. Kim7
- Department of Rheumatology, Ajou University School of Medicine, Suwon, Republic of Korea.
- Division of Rheumatology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
- Department of Rheumatology, Ajou University School of Medicine, Suwon, Republic of Korea.
- Department of Rheumatology, Ajou University School of Medicine, Suwon, Republic of Korea.
- Division of Rheumatology, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.
- Department of Mathematics, College of Natural Sciences, Hanyang University, Seoul, Republic of Korea. sklee8204@gmail.com
- Department of Rheumatology, Ajou University School of Medicine, Suwon, Republic of Korea. nakhada@naver.com
CER17390
2024 Vol.42, N°9
PI 1781, PF 1791
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 38634363 [PubMed]
Received: 19/12/2023
Accepted : 15/03/2024
In Press: 16/04/2024
Published: 23/09/2024
Abstract
OBJECTIVES:
This study aimed to identify the risk factors associated with overall adverse events (AEs) and infections in patients with rheumatoid arthritis (RA) and comorbid interstitial lung disease (ILD), receiving biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs), using data from the Korean College of Rheumatology Biologics registry.
METHODS:
We analysed data from a cohort of 2,266 adult patients with RA who received b/tsDMARDs, including 169 patients with comorbid ILD. We identified the risk factors for overall AEs and infections in both the all RA group and the subgroup of patients with RA-ILD and investigated the impact of infections on mortality in patients with RA-ILD.
RESULTS:
Among all patients with RA, 45.7% withdrew b/tsDMARDs, whereas among those with RA-ILD, a higher proportion of 57.4% withdrew their treatment regimen. The main reason for withdrawing b/tsDMARDs in the RA-ILD group was AEs, with infections accounting for the largest proportion of reported AEs. In multivariable analysis of the risk factors for overall AEs and infections in the RA-ILD group, older age was identified as a risk factor for overall AEs (odds ratio [OR], 3.01; p=0.014), and only a current smoking status was identified as a risk factor for infections (OR, 2.11; p=0.035).
CONCLUSIONS:
Patients with RA-ILD exhibited a higher rate of b/tsDMARDs withdrawal due to overall AEs and infections than those with RA without ILD. In the RA-ILD group, older age was identified as a risk factor for overall AEs, whereas a current smoking status was identified as a risk factor for infections.
